Annals of Oncology 13:1743-1748, 2002
© 2002 European Society for Medical Oncology
Original Paper |
In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines
Centre Alexis Vautrin, Laboratoire de Recherche en Oncologie, Vandoeuvre-les-Nancy, France
Received 26 October 2001; revised 4 April 2002; accepted 17 April 2002
Background:
Trastuzumab (Herceptin®) has clinical indication in association with paclitaxel (Taxol®) for the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer. Synergistic interactions have been reported with taxane derivatives in HER2-expressing breast cancer cells. However, no direct comparison of the potential interest in combining trastuzumab with either paclitaxel or docetaxel (Taxotere®) has been reported.
Materials and methods:
The present study was designed to evaluate in a comparative way the interaction of trastuzumab with paclitaxel or docetaxel in HER2-overexpressing human breast cancer cell lines. HER2 expression was documented in MCF-7, MDA-MB453 and SK-BR3 cell lines using immunocytochemistry with purified mouse anti-human monoclonal antibody. Cytotoxicity assays were performed using the sulforhodamine B assay and in vitro interactions between trastuzumab and taxanes were analyzed using the median-effect principle.
Results:
Trastuzumab cytotoxicity was confirmed to be directly related to HER2 expression level. At the IC50, the combination of trastuzumab with either paclitaxel or docetaxel led to synergism in all cell lines. However, considering mean values calculated in the IC30–IC70 range of concentrations, trastuzumab interacted additively with docetaxel in SK-BR3 and MDA-MB453 cell lines while additive and synergistic interactions were achieved with paclitaxel in SK-BR3 and MDA-MB453, respectively. On the same basis, trastuzumab yielded synergistic interaction with both taxanes in the MCF-7 cell line.
Conclusions:
The present study shows that at least additive interactions are observed when trastuzumab is combined with either paclitaxel or docetaxel in weak to moderate or more than moderate HER2-expressing cells. Some interesting results were achieved in cells displaying weak HER2 expression which could suggest some further potential interest in trastuzumab.
Key words: docetaxel, HER2, paclitaxel, trastuzumab
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. L. Spector and K. L. Blackwell Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer J. Clin. Oncol., December 1, 2009; 27(34): 5838 - 5847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer Ann. Onc., February 1, 2008; 19(2): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marangoni, A. Vincent-Salomon, N. Auger, A. Degeorges, F. Assayag, P. de Cremoux, L. de Plater, C. Guyader, G. De Pinieux, J.-G. Judde, et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays Clin. Cancer Res., July 1, 2007; 13(13): 3989 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Harris, A. D. Gilliam, A. J. McKenzie, S. A. Evans, A. M. Grabowska, P. A. Clarke, D. F. McWilliams, and S. A. Watson The Biological and Therapeutic Importance of Gastrin Gene Expression in Pancreatic Adenocarcinomas Cancer Res., August 15, 2004; 64(16): 5624 - 5631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Lorenzo, A. Arciello, R. Cozzolino, D. B. Palmer, P. Laccetti, R. Piccoli, and G. D'Alessio A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas Cancer Res., July 15, 2004; 64(14): 4870 - 4874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Corsini, P. Mancuso, S. Paul, A. Burlini, G. Martinelli, G. Pruneri, and F. Bertolini Stroma Cells: A Novel Target of Herceptin Activity Clin. Cancer Res., May 1, 2003; 9(5): 1820 - 1825. [Abstract] [Full Text] [PDF]
|
|